Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; purified talc; disodium edetate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - amitriptyline alphapharm 50mg tablets are indicated only for the maintenance treatment of major depression. (see precautions). nocturnal enuresis where organic pathology has been excluded.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. entrip 50mg tablets are indicated only for the maintenance treatment of major depression (see precautions). nocturnal enuresis where organic pathology has been excluded.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: colloidal anhydrous silica; macrogol 6000; maize starch; purified talc; crospovidone; magnesium stearate; microcrystalline cellulose; sunset yellow fcf aluminium lake; lactose monohydrate; hypromellose; titanium dioxide; indigo carmine aluminium lake - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; lactose monohydrate; crospovidone; maize starch; hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; colloidal anhydrous silica; macrogol 6000; indigo carmine aluminium lake - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.

Kanada - Ingliż - Health Canada

hoffmann-la roche limited - levodopa; benserazide (benserazide hydrochloride) - capsule - 50mg; 12.5mg - levodopa 50mg; benserazide (benserazide hydrochloride) 12.5mg - dopamine precursors

Stati Uniti - Ingliż - NLM (National Library of Medicine)

amneal pharmaceuticals llc - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 95 mg - rytary is indicated for the treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. rytary is contraindicated in patients: - currently taking a nonselective monoamine oxidase (mao) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective mao inhibitor. hypertension can occur if these drugs are used concurrently [see drug interactions (7.1)] . risk summary there are no adequate data on the developmental risk associated with the use of rytary in pregnant women. in animal studies, carbidopa-levodopa has been shown to be developmentally toxic (including teratogenic effects) at clinically relevant doses (see data). the estimated background risk of major birth defects and miscarriage in the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% a

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose - levodopa/carbidopa gppl is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gppl frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; crospovidone - levodopa/carbidopa genpar is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa genpar frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; quinoline yellow aluminium lake; crospovidone; microcrystalline cellulose; pregelatinised maize starch - levodopa/carbidopa gppl is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gppl frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.